Kevin Kunzmann

The current pox virus outbreak has become closely synonymous with fewer lesions than past mpox—but dermatology guidance is needed all the same.

New phase 2b findings support the oral JAK1 inhibitor's capability to improve repigmentation versus placebo.

Symptoms including vestibular rashes and COVID toes have become less synonymous with SARS-CoV-2 infection. Why is that?

As the pandemic passes its third year, one dermatologist foresees their field's own pursuit of specialty-specific vaccination guidelines.

New phase 2b data show the oral PDE4 inhibitor could reduce psoriasis area severity by more than 60% in 16 weeks.

A small molecule IL-17A inhibitor, izokibep has additionally shown efficacy in treating psoriatic arthritis—and will now be reviewed in a phase 3 HS trial.

Pediatric dermatologist Mercedes Gonzalez, MD, discusses the new phase 3 B-SIMPLE data supporting berdazimer gel as the first potential molluscum treatment.

New phase 3 data from the BRAVE-AA trial program showed some patients who had little response to initial baricitinib achieved hair growth in year 2 of treatment.

The Icahn investigator reviews new data suggesting ethnicity-based differences in molecular phenotype of atopic dermatitis, which may better inform treatment strategies for different populations.

New phase 3 DELTA 1 trial data show the topical pan-JAK inhibitor doubled the rate of treatment success versus vehicle cream.

New long-term extension data from the pivotal TRuE-V program show treatment continuation, as well as post-relapse re-initiation, is efficacious and safe in patients.

After last year's historic approval, investigators want to learn more about their available drug regimens, as well as pediatric eligibility.

Three years into the pandemic, dermatologists have become more confident in discussing vaccine issues with their patients, including the misunderstood risk of disease flare-up associated with boosters.

The University of Toronto expert discusses therapy switching, JAK inhibitor initiation, comorbidity cross-benefit, and more at AAD 2023.

Amid the introduction of immunosuppressant therapies and the ongoing pandemic, dermatologists find themselves guiding new decisions for patient treatment around vaccinations.

Little head-to-head data exists between JAK inhibitors and biologics, but common metrics of treatment success can help physicians navigate newer agents.

The UMass Chan chair of dermatology recaps a historic year of development for the chronic disease, including the progression of even newer treatment options.

The Mount Sinai Dermatology chair reviews headlines from the 2022 meeting before sharing perspective on developing drugs and topics.

Beyond the obvious benefits, the practice of remote and in-clinic photography is altering treatment capabilities.

The St. Jude oncologist discusses the 30-year development of pediatric melanoma interpretation.

In addition to sharing how a novel machine learning method may one day soon predict lung disease susceptibility, Kalhan describes the science behind the ALA Lung Health Cohort Research Study.

A new review considered the progression of 4 treatment options being researched and developed for the treatment of the progressive form of vision loss.

A new survey analysis delves into Americans' perspective on the CDC, and local and state health departments, and their handling of the pandemic.

New pooled data from DISCOVER-1 and DISCOVER-2 show the injection biologic provided full resolution of dactylitis in three-fourths of patients by week 52.

A cohort analysis from Norway suggests women with active psoriatic arthritis or axial spondylitis are at greater risk of either elective or emergency delivery procedures.

A new study from China shows predictive value of baseline PCV presence and PED characteristics among patients with nAMD receiving conbercept.

An international pilot study shows a probiotic candidate may improve both management of gout and relevant blood serum levels in treated patients.

A one-of-its-kind assessment of 8 decades' worth of UK data show a lower respiratory tract infection by age 2 increases risk of premature adult death by 93%.

New cohort analysis data show women with fibromyalgia are at an increased risk of depression—which is also correlated with a worse life expectancy over 8 years.

A new study supports an individualized treatment plan for aflibercept, showing its improved efficacy with fewer injections over 2 years.